Cu 64-DOTA-pembrolizumab

N/A

Report date: 2025/09/24 16:01:02

First In Class

Base Information

Drug NameCu 64-DOTA-pembrolizumab

Drug Alias NameCopper Cu 64-DOTA-pembrolizumab64Cu-DOTA-pembrolizumab64CDP

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radioactive diagnostic agent +[4]

Mechanisms of ActionProgrammed cell death protein 1 blockersPositron-emission tomography enhancers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCity Of Hope National Medical Center National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute City Of Hope National Medical Center

Active IndicationsN/A

Inactive IndicationsSolid tumoursHematologic NeoplasmsLymphoma

Other Information

ATC CodeN/A